Affymax Inc Com (NASDAQOTH:AFFY)

CAPS Rating: 1 out of 5

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

Results 1 - 14 of 14

Recs

0
Member Avatar EarlLP (< 20) Submitted: 1/16/2014 9:49:56 PM : Underperform Start Price: $0.92 AFFY Score: +92.75

All of AFFY egg's are in one basket > Omontys, check it out Omontys is off the market.

my pick GILD

Recs

0
Member Avatar acts20 (38.51) Submitted: 4/3/2013 3:40:34 PM : Outperform Start Price: $1.16 AFFY Score: -115.23

Drug will B reinstated

Recs

0
Member Avatar stil370 (53.65) Submitted: 3/31/2013 7:58:22 PM : Underperform Start Price: $1.44 AFFY Score: +116.63

wsj online report

http://bit.ly/YWu6XW

these guys were rotten to the core

Recs

0
Member Avatar Litigation (22.92) Submitted: 3/16/2013 7:19:29 PM : Outperform Start Price: $3.00 AFFY Score: -122.50

Price Target: $8

Recs

0
Member Avatar prstout (81.28) Submitted: 2/25/2013 9:35:40 AM : Outperform Start Price: $2.55 AFFY Score: -123.36

High risk situation, however the price is more like a call option.

Recs

0
Member Avatar BioPharmacist (< 20) Submitted: 12/12/2012 1:51:37 AM : Underperform Start Price: $23.25 AFFY Score: +135.17

Their anemia drug partnered with takeda will show disappointing sales numbers with a slow start.

Recs

2
Member Avatar dkoeper (< 20) Submitted: 4/7/2011 8:52:11 AM : Outperform Start Price: $5.94 AFFY Score: -144.39

Hematide will get approved in the dialysis setting where its phase 3 clinical trials showed a trend toward superiority when compared with aranesp. The dialysis market is much larger than the non-dialysis market

Recs

0
Member Avatar kenqc (62.22) Submitted: 2/25/2011 3:45:18 PM : Outperform Start Price: $6.59 AFFY Score: -145.79

pending fda approval, good cash position, unique technology

Recs

0
Member Avatar punchy22 (< 20) Submitted: 6/28/2010 11:24:30 AM : Underperform Start Price: $6.75 AFFY Score: +178.89

This company is dead.

Recs

0
Member Avatar crichton1 (< 20) Submitted: 10/9/2009 5:54:26 PM : Outperform Start Price: $22.79 AFFY Score: -180.80

competitive product to Amgen's EPO on the horizon.

Recs

0
Member Avatar power2macs (< 20) Submitted: 7/8/2009 3:13:37 AM : Outperform Start Price: $17.84 AFFY Score: -220.95

the co hasnt had any major catalysts for a while since its in the middle of a moderately large phase iii program. as the market begins to remember that affys pivotal data is coming up it will also recall that the market for their drug hematide is absolutely massive.

there are some caveats to the large mkt opp (jnj litigation, potential generic biologics legislation, and a stagnant market for ESAs), but despite this the co remains dramatically undervalued, particularly considering their $150m cash balance (which mgmt has said will not be sufficient to carry them thru to profitability tho).

Recs

0
Member Avatar equalfuture (21.10) Submitted: 4/10/2008 4:50:46 AM : Outperform Start Price: $13.82 AFFY Score: -148.79

MAJOR BUY: 9 per share, i am buying when this company hits nine dollars,

good price at 9 per share, can not go wrong, i am reaching for a nine dollar per share price for June.

Recs

1
Member Avatar ArlenesX (< 20) Submitted: 4/27/2007 1:23:01 PM : Outperform Start Price: $34.04 AFFY Score: -137.93

IPO'd in 12/06. A great to superior market for the product, going into FDA stage 3. Once it is ok'd for sale it will reduce the dosage for anemia/cancer patients with kidney/dialysis related conditions by cutting treatment at least in half.
The potential is enormous with the market growing everyday.

Recs

1
Member Avatar NetscribeBiotech (95.39) Submitted: 3/27/2007 9:14:37 AM : Underperform Start Price: $34.00 AFFY Score: +143.98

Affymax is a biopharmaceutical company creating peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The company was spun out from GlaxoSmithKline in 2001. The company does not have any approved product in its portfolio. Its lead product candidate Hematide is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for anemia due to chronic kidney disease (CKD) and cancer. Besides this it has number of products in pre clinical phase for neutropenia, tissue protection and cancer.

The company is yet to break-even. However the company is in nascent stage and thus one can form a view on this company on the basis of its financial performance. The most relevant factor for such stocks would be the commercial potential of its pipe-line.

Affymax’s lead product candidate Hematide targets multi-billion-dollar worldwide EPO (erythropoietin) market for treating anemia. As a matter of fact The EPO market for anemia valued at $10.0 billion plus is the largest and most lucrative market in biotech at roughly plus worldwide and still growing. The drug has shown clear efficacy in Phase II trials and has the competitive advantage of less frequent dosing. The company has also roped in Takeda to market its product.

This budding company also has some issues to grapple with the chief among them would be arbitration with Johnson and Johnson to determine ownership of several key Hematide patents. In the event of an unfavorable outcome the company might have to share or lose the rights over patents.

The company’s valuation seems rich. It is true that its pipeline targets lucrative market opportunities but they will take some time to fructify. Hemadite for anemia is expected to enter Phase III in second half of 2007. The macro economic environment is such that people prefer stable cash flows and proven stories. Thus these types of stories which require people to bet aggressively on the future might not find favor in today’s market. Hence the company might under perform.

Results 1 - 14 of 14

Featured Broker Partners


Advertisement